



(51) International Patent Classification:

C12N 5/00 (2006.01) *C12R 1/145* (2006.01)
C07K 14/33 (2006.01)

(21) International Application Number:

PCT/KR2016/004430

(22) International Filing Date:

28 April 2016 (28.04.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2015-0059654 28 April 2015 (28.04.2015) KR

(71) Applicant: **DAEWOOONG CO., LTD.** [KR/KR]; 244,
Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do
13211 (KR).

(72) Inventors: **KIM, Kyoung-Yun**; 103-1303, 50, Hwas-
ancheonbyeon-ro, Wansan-gu, Jeonju-si, Jeollabuk-do
54970 (KR). **SUL, Hye-Young**; 326-302, 17, Jungang-
gongwon-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
13588 (KR). **MIN, Kyoung-Min**; No. 502, 321,
Hongcheon-ro, Hongcheon-eup, Hongcheon-gun, Gang-
won-do 25136 (KR).

(74) Agents: **LEE, Cheo Young** et al.; 11F., 123, Teheran-ro,
Gangnam-gu, Seoul 06133 (KR).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ,
LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA,
PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: MEDIUM COMPOSITION FOR PREPARING BOTULINUM TOXIN



(57) Abstract: The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of *Clostridium* sp. capable of producing botulinum toxin. The medium composition of the present invention comprises at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones and minerals, is used for culture of *Clostridium botulinum*, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.

Description

Title of Invention: MEDIUM COMPOSITION FOR PREPARING BOTULINUM TOXIN

Technical Field

- [1] The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of strains of *Clostridium* capable of producing botulinum toxin. The medium composition of the present invention comprises at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate.

[2]

Background Art

- [3] A variety of *Clostridium* sp. strains that secrete neurotoxic toxins have been discovered since 1890s, and the characterization of toxins that are secreted from these bacteria has been made for the past 70 years (Schant, E. J. *et al.*, *Microbiol. Rev.*, 56:80, 1992).
- [4] Neurotoxic toxins derived from the *Clostridium* sp., that is, botulinum toxins, are classified into seven serotypes (serotypes A to G) depending on their serological properties. Each of the toxins has a toxin protein having a size of about 150 kDa and naturally contains a complex of several non-toxic proteins bound thereto. A medium complex (300 kDa) is composed of a toxin protein and a non-toxic non-hemagglutinin protein, and a large complex (450 kDa) and a very large complex (900 kDa) are composed of the medium-sized complex bound to hemagglutinin (Sugiyama, H., *Microbiol. Rev.*, 44:419, 1980). Such non-toxic hemagglutinin proteins are known to function to protect the toxin from low pH and various proteases in the intestines.
- [5] The toxin is synthesized as a single polypeptide having a molecular weight of about 150 kDa in cells, and then cleaved at a position of 1/3 starting from the N-terminal end by the action of intracellular protease or treatment with an artificial enzyme such as trypsin into two units: a light chain (L; molecular weight: 50 kDa) and a heavy chain (H; molecular weight: 100 kDa). The cleaved toxin has greatly increased toxicity compared to the single polypeptide. The two units are linked to each other by a disulfide bond and have different functions. The heavy chain binds to a receptor of a target cell (Park, M.K. *et al.*, *FEMS Microbiol. Lett.*, 72:243, 1990) and functions to interact with a biomembrane at low pH (pH 4) to form a channel (Mantecuccio, C. *et al.*, *TIBS.*, 18:324, 1993), and the light chain has the pharmacological activity of interfering the secretion of neurotransmitters, when it is permeable to cells or introduced

- by electroporation or etc (Poulain, B. *et al.*, *Proc. Natl. Acad. Sci. USA.*, 85:4090, 1988).
- [6] The toxin inhibits the exocytosis of acetylcholine at the cholinergic presynapse of a neuromuscular junction to cause asthenia. It has been considered that even treatment with a very small amount of the toxin exhibits toxicity, suggesting that the toxin has any enzymatic activity (Simpson, L. L. *et al.*, *Ann. Rev. Pharmacol. Toxicol.*, 26:427, 1986).
- [7] According to a recent report, the toxin has metallopeptidase activity, and its substrates include composed of synaptobrevin, syntaxin, a synaptosomal associated protein of 25 kDa (SNAP25), etc., which are the unit proteins of an exocytosis machinery complex. Each type of toxin uses one of the above-described three proteins as its substrate, and it is known that type B, D, F and G toxins cleave synaptobrevin at a specific site, type A and E toxins cleave SNAP25 at a specific site, and type C cleaves syntaxin at a specific site (Binz, T. *et al.*, *J. Biol. Chem.*, 265:9153, 1994).
- [8] Particularly, type A botulinum toxin is known to be soluble in a dilute aqueous solution at a pH of 4.0-6.8. It is known that a stable non-toxic protein is separated from neurotoxin at a pH of about 7 or higher, and as a result, the toxicity is gradually lost. Particularly, it is known that the toxicity decreases as pH and temperature increase.
- [9] The botulinum toxin is fatal to the human body even in small amounts and is easy to produce in large amounts. Thus, it constitutes four major bio-terror weapons together with *Bacillus anthracis*, *Yersinia pestis* and smallpox virus. However, it was found that, when type A botulinum toxin is injected at a dose that does not systematically affect the human body, it can paralyze local muscle in the injected site. Based on this characteristic, type A botulinum toxin can be used in a wide range of applications, including wrinkle removing agents, agents for treating spastic hemiplegia and cerebral palsy, etc. Thus, the demand for type A botulinum toxin has increased, and studies on methods of producing botulinum toxin so as to satisfy the demand have been actively conducted.
- [10] A current typical commercial product is BOTOX® (a purified neurotoxin complex of type A botulinum toxin) that is commercially available from Allergan, Inc., USA. A 100-unit vial of BOTOX® is composed of about 5 ng of a purified neurotoxin complex of type A botulinum toxin, 0.5 mg of human serum albumin and 0.9 mg of sodium chloride and is reconstituted using sterile saline without a preservative (injection of 0.9% sodium chloride). Other commercial products include Dysport® (a complex of *Clostridium botulinum* type A toxin and hemagglutinin, which has lactose and human serum albumin in a pharmaceutical composition comprising botulinum toxin and is reconstituted using 0.9% sodium chloride before use) that is commercially available from Ipsen Ltd., UK, MyoBloc® (an injectable solution (a pH of about 5.6) comprising botulinum type B toxin, human serum albumin, sodium succinate and sodium chloride)

that is commercially available from Solstice Neurosciences, Inc.

- [11] A medium for culture of *Clostridium botulinum*, which is generally used in a method for production of botulinum toxin as disclosed in Korean Patent No. 10-1339349, contains animal components. Thus, if an animal abnormal prion known as an agent that causes transmissible spongiform encephalopathy is contained in the animal components due to contamination, it poses problems in a process for producing botulinum toxin.
- [12] Transmissible spongiform encephalopathy (TSE) is known as a neurodegenerative disorder causing serious degeneration of neurons, and examples thereof includes bovine spongiform encephalopathy (BSE), Scrapie, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, Kuru, transmissible mink encephalopathy, chronic wasting disease, feline spongiform encephalopathy, etc., which affect humans and animals. It was reported that BSE crosses the species barrier and infects even humans.
- [13] The agent that causes transmissible spongiform encephalopathy (TSE) has characteristics in that it has no immunogenicity and the incubation period is long. From histopathological analysis of BSE-affected bovine brain tissue, it can be seen that special spongiform vacuoles were formed in the brain due to damage to neurons and deposition of abnormal protein fibers.
- [14] The cause of TSE is a proteinaceous infectious particle known as the abnormal prion. Unlike general viruses that require nucleic acid, the abnormal prion is an infectious particle composed of protein alone without containing nucleic acid. Regarding TSE, it is known that, when an abnormal prion (PrP^{sc}) that is an infectious particle binds to a normal prion (PrP^c), it is converted to a pathogenic prion which is then accumulated in the brain (Prusiner SB, *AlzheimerDis Assoc Disord.*, 3:52-78, 1989).
- [15] Creutzfeldt-Jakob disease is a rare neurodegenerative disorder of human transmissible spongiform encephalopathy (TSE) where the transmissible agent is apparently an abnormal isoform of a prion protein. An individual with Creutzfeldt-Jacob disease can deteriorate from apparent perfect health to akinetic mutism within six months. Thus, a potential risk may exist of acquiring a prion mediated disease, such as Creutzfeldt-Jacob disease, from the administration of a pharmaceutical composition which contains a biologic, such as a botulinum toxin, obtained using animal-derived products. Thus, if a pharmaceutical composition is prepared by drug substance produced using animal-derived components, it can subject the patient to a potential risk of receiving various pathogens or infectious agents.
- [16] Under this technical background, the present inventors have found that, when a medium comprising transmissible spongiform encephalopathy(TSE)-free plant-derived peptone and mineral components is used for culture of *Clostridium botulinum* in order

to prevent the risk of developing the above-described prion-mediated disease, the risk of development of the prion-mediated disease that can occur in a medium that is in current use (original medium) can be excluded, and the growth rate of *Clostridium botulinum* in the medium can be increased compared to that in the medium that is in current use, thereby completing the present invention.

[17]

[18]

Disclosure of Invention

Technical Problem

[19] It is an object of the present invention to provide a medium composition comprising plant-derived peptones having no risk of transmissible spongiform encephalopathy (TSE) infection, and a method for production of botulinum toxin, which improves the production of botulinum toxin by culturing *Clostridium botulinum* in the medium composition.

[20]

Solution to Problem

[21] To achieve the above object, the present invention provides a medium composition for culture of *Clostridium botulinum*, the medium composition comprising: at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate.

[22] The present invention also provides a method for producing botulinum toxin, comprising the steps of: (a) culturing *Clostridium botulinum* using the above-described medium composition to produce botulinum toxin; and (b) recovering the produced botulinum toxin.

[23]

Brief Description of Drawings

[24] FIG. 1 shows the growth of *Clostridium botulinum* in a medium (APF medium) containing plant-derived peptones.

[25] FIG. 2 shows the growth of *Clostridium botulinum* in a medium containing plant-derived peptones, minerals, amino acids and vitamins.

[26] FIG. 3 shows the results of examining whether a precipitate is formed after sterilization of a medium containing plant-derived peptones, minerals, amino acids and vitamins.

[27] FIG. 4 shows the results of examining whether a precipitate is formed after sterilization of a medium containing plant-derived peptones and minerals.

[28] FIG. 5 shows the growth of *Clostridium botulinum* in media obtained by additionally adding vitamins, amino acids and "BD Recharge™ without Glucose and L-Glutamine"

to media for culture of the bacterium, which contain plant-derived peptones and minerals.

[30] FIG. 6 shows the growth of *Clostridium botulinum* in media for culture of the bacterium, which contain various kinds of plant-derived peptones.

[31] FIG. 7 shows contour plots of FFD for mineral screening, and response optimization. FIG. 7a contour plot for high setting; FIG. 7b contour plot for middle setting; FIG. 7c contour plot for low setting; and FIG. 7d response optimization for maximum OD.

[32] FIG. 8 shows contour plots of FFD for mineral screening, and response optimization. FIG. 8a contour plot for high setting; FIG. 8b contour plot for middle setting; FIG. 8c contour plot for low setting; and FIG. 8d response optimization for maximum OD.

[33] FIG. 9 shows contour plots for plant peptone screening, and response optimization. FIG. 9a contour plot for middle setting; FIG. 9b contour plot for low setting; and FIG. 9c response optimization for maximum OD.

[34] FIG. 10 shows the growth curve of *Clostridium botulinum* in the finally selected APF medium, and a change in toxin concentration.

[35]

[36] **Best Mode For Carrying Out The Invention**

[37] In the present invention, it was attempted to prepare a medium that further increases the growth rate of *Clostridium botulinum* compared to a medium that is in current use (original medium) and have no risk of infection with TSE or the like. Thus, an animal protein-free (APF) medium containing plant-derived peptones were used, and the growth of a bacterium in the APF medium was examined. As a result, the APF medium showed an increased growth rate of the bacterium compared to a medium that is in current use. Thus, if the APF medium is used, a high concentration of botulinum toxin can be produced by culturing a bacterium in a safe manner under TSE-free conditions.

[38] As used herein, the term “medium that is in current use or original medium” means a medium comprising casein hydrolysate, yeast extract and thioglycollate medium, which are animal-derived medium components. The term “APF medium (animal protein-free medium)” means a medium that contains no animal-derived protein and that contains plant-derived peptones, minerals and glucose.

[39] In an example of the present invention, in order to produce botulinum toxin by culturing *Clostridium botulinum* under transmissible spongiform encephalopathy (TSE)-free conditions, an APF medium comprising TSE-free plant-derived peptone was prepared and compared with a medium that is in current use (containing an animal component). As a result, it could be seen that an optimal medium composition for culturing *Clostridium botulinum* is one comprising a plant-derived peptone, at least one mineral selected from the group consisting of KH_2PO_4 , K_2HPO_4 and Na_2HPO_4 , and

a carbon source (e.g., glucose), and the optimal growth of the bacterium in this medium was found. As a result, as shown in Table 13, it was determined that the optimal contents of plant-derived peptones in the finally selected medium composition for culture of *Clostridium botulinum* are 5 g/L Hy-Pea™ 7404, 10 g/L UltraPep™ Cotton and 5 g/L HyPep™ 4601N, and the optimal contents of minerals in the medium composition are 5.5 g/L K₂HPO₄ and 3g/L Na₂HPO₄.

[40] In another example of the present invention, the growth pattern of *Clostridium botulinum* in the finally selected APF medium comprising plant-derived peptones and minerals, and the toxin concentration were measured. As a result, as shown in Table 12 and FIG. 10, the OD value started to increase after 12 hours of culture of *Clostridium botulinum*, and at 24 hours of culture, the culture medium showed an OD_{540nm} of 3.5465 and an OD_{600nm} of 3.0695. Then, the OD value decreased gradually, and at 48 hours of culture, the culture medium showed an OD_{540nm} of 0.792 and an OD_{600nm} of 0.7224. The toxin concentration in the culture supernatant of *Clostridium botulinum* started to increase after 5 hours of culture and showed a final value of 31.41 µg/ml. When the toxin concentration was measured after rupturing the bacterium, the toxin started to be produced after 5 hours of culture, and the toxin concentration continued to increase, was maintained at a uniform level after 28 hours of culture, and showed a final value of 38.39 µg/ml.

[41] Based on this, in one aspect, the present invention is directed to a medium composition for culture of *Clostridium botulinum*, the medium composition comprising: at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate.

[42] As used herein, the term "plant-derived peptone" means a peptone extracted from garden pea, cotton seed or wheat gluten. Preferably, the plant-derived peptone may be commercially available Hy-Pea™ 7404, UltraPep™ Cotton, HyPep™ 7504 or HyPep™ 4601N, but is not limited thereto.

[43] As used herein, the term "plant-derived peptone" or "plant-derived hydrolysate" means a product obtained by degrading a protein isolated from a plant. For example, the garden pea peptone (garden pea hydrolysate) means a product obtained by degrading a total protein isolated from garden pea.

[44] Degradation of the plant-derived protein is preferably performed by partial digestion. Degradation of the protein is preferably performed by acid treatment, base treatment, enzyme treatment, high-pressure treatment, heat treatment or physical treatment. More preferably, the plant-derived peptone may be one obtained by enzyme treatment. The physical treatment is, for example, grinding.

[45] The plant-derived peptone that is used in the present invention is a partial degradation product of plant-derived protein, is a mixture comprising not only amino

acids that are single molecules, but also peptides composed of several to several tens of amino acids, and intact protein molecules.

[46] In the present invention, the content of the plant-derived peptones in the medium composition may be 0.1-10 w/v% (1-100 g/L), preferably 0.2-5 w/v% (2-50 g/L), more preferably 0.5-2 w/v% (5-20 g/L).

[47] In the present invention, the medium composition contains all the garden pea hydrolysate, the cotton seed hydrolysate and the wheat gluten hydrolysate, and the content ratio of the garden pea hydrolysate, the cotton seed hydrolysate and the wheat gluten hydrolysate in the medium composition may be 1:0.24-43.62:0.01-50.57 by weight, preferably 1:0.68-14.46:0.09-9.87 by weight, more preferably 1:1.6-2.4:0.6-1.4 by weight.

[48] In the present invention, the medium composition for culture of *Clostridium botulinum* may further contains a carbon source and at least one mineral selected from the group consisting of K₂HPO₄ (dipotassium phosphate), Na₂HPO₄ (disodium phosphate) and KH₂PO₄ (monopotassium phosphate).

[49] Herein, examples of the carbon source include, but are not limited to, monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, starch, etc.), sugar alcohols (e.g., xylitol, sorbitol, erythritol, etc.).

[50] In the present invention, the content of the mineral in the medium composition may be 0.05-3.5 w/v% (0.5-35 g/L), preferably 0.1-1.75 w/v% (1-17.5 g/L), and more preferably 0.25-0.7 w/v% (2.5-7 g/L).

[51] In another aspect, the present invention is directed to a method for producing botulinum toxin, comprising the steps of: (a) culturing *Clostridium botulinum* using the above-described medium composition to produce botulinum toxin; and (b) recovering the produced botulinum toxin.

[52] In the present invention, the culturing may be performed under anaerobic conditions, and the botulinum toxin may be selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

[53]

[54] Examples

[55] Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are illustrative purposes only and are not to be construed to limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

[56]

[57] Example 1: Culture of *Clostridium botulinum* in Plant-derived Peptone Medium

[58] 1-1: Composition of a Medium Currently Used in Culture

[59] The reagents and medium components used in the present invention were purchased from Sigma (USA), Kerry Inc. (USA), BD Biosciences (USA), Gibco Life Technologies (USA), and Quest (USA).

[60] A medium that is in current use having a composition comprising 2% casein hydrolysate (20 g/L), 1% yeast extract (10 g/L), 1% glucose (10 g/L) and 0.5% thioglycollate medium (5 g/L) was used for the seed culture and main culture of *Clostridium botulinum* to produce botulinum toxin. 5g of the thioglycollate medium per liter of the medium that is in current use is composed of 2.52 g of an enzymatic digest of casein, 0.84 g of yeast extract, 0.925 g of dextrose, 0.085 g of sodium thioglycollate, 0.42 g of NaCl, 0.085 g of L-cysteine, 0.00014 g of Resazurin and 0.125 g of bacteriological agar.

[61]

[62] 1-2: Composition of APF Medium Used in Culture

[63] A negative control medium was prepared by removing casein hydrolysate, yeast extract and thioglycollate medium from the medium that is in current use (original medium) for culture of *Clostridium botulinum*, and an animal protein-free (APF) medium was prepared by adding four plant-derived peptone candidates (Hy-Pea™ 7404, UltraPep™ Cotton, HyPep™ 7504, and HyPep™ 4601N) to the negative control medium (Table 1).

[64]

[65] Table 1 shows the components of the plant-derived peptone-containing APF medium for culture of *Clostridium botulinum* in comparison with the medium that is in current use.

[66]

[67] [Table 1]

Components of Medium	Conc. (g/L)	medium that is in current use	Negative Control	APF Medium
Glucose	10	10	10	10
Sodium Chloride (NaCl)	0.42	0.42	0.42	0.42
Casein hydrolysate	20	20	-	-
Yeast extract	10	10	-	-
Thioglycollate medium	5	5	-	-
Hy-Pea™ 7404	20	-	-	20
UltraPep™ Cotton	10	-	-	10
HyPep™ 7504	10	-	-	10
HyPep™ 4601N	10	-	-	10

[68]

[69] 1-3: Seed Culture of *Clostridium botulinum*

[70] 20 µl of *Clostridium botulinum* (the Korean Centers for Disease Control and

Prevention Accession No.: 4-029-CBB-IS-001) was inoculated into a culture tube containing 10 ml of a sterile medium having each of the compositions described in Examples 1-1 and 1-2 and was subjected to primary seed culture (stationary culture) at 35°C for 22-30 hours under anaerobic conditions. When the growth of the bacterium in the primary seed culture was confirmed, 8 ml of the primary seed culture was inoculated into a 1-liter culture bottle containing 800 ml of a sterile medium having the same medium composition and was subjected to secondary seed culture (stationary culture) at 35°C for 8-15 hours under anaerobic conditions.

[71]

[72] 1-4 : Main Culture of *Clostridium botulinum*

[73] In order to produce a botulinum toxin by culturing *Clostridium botulinum*, the main culture of the bacterium was performed. Specifically, 9.3 L of a medium having each of the compositions described in Examples 1-1 and 1-2 was prepared and placed in a 10-liter incubator, followed by sterilization of the medium. Nitrogen was supplied to make anaerobic conditions, and the growth of the bacterium was performed at a temperature of 35°C and an agitation speed of 50 rpm.

[74] The secondary seed culture in the 1-liter culture bottle in Example 1-3 was inoculated into a 10-liter incubator through an inoculation line connected to the inoculation port of the 10-liter incubator. *Clostridium botulinum* in the 10-liter incubator was cultured under the conditions of 35°C and 50 rpm and the set culture conditions were monitored and recorded. When the bacterium was cultured for 100 hours or more, the main culture was terminated.

[75] The growth of *Clostridium botulinum* in the animal protein-free (APF) medium prepared by adding four plant-derived peptone candidates (Hy-Pea™ 7404, UltraPep™ Cotton, HyPep™ 7504, and HyPep™ 4601N) to the negative control medium was compared with that of the bacterium in the negative control medium prepared by removing casein hydrolysate, yeast extract and thioglycollate medium from the medium that is in current use (original medium) (Table 1).

[76] As a result, as shown in Table 1 and FIG. 1, *Clostridium botulinum* did not grow in the negative control medium, but started to grow in the original medium (medium that is in current use) at 24 hours after inoculation of the bacterium and started to grow in the plant-derived peptone-containing medium at 30 hours after inoculation of the bacterium.

[77]

[78] Example 2: Culture of *Clostridium botulinum* in Medium Containing Plant-derived Peptones, Minerals, Amino Acids and Vitamins

[79] Because the growth of *Clostridium botulinum* in the medium prepared by adding four plant-derived peptones in Example 1 was slower than that in the original medium,

solutions thereto were provided as follows.

[80] 1) To examine the effect of thioglycollate functioning to make anaerobic conditions, thioglycollate was removed from the original medium (medium that is in current use), and a change in the growth rate of the bacterium in the thioglycollate-free medium was analyzed.

[81] 2) Because the slower growth rate could be because of the lack of the nitrogen source, the peptone concentration in the medium used for culture of the bacterium was increased two times.

[82] 3) The growth of *Clostridium botulinum* in a medium obtained by adding minerals, amino acids and vitamins to the plant-derived peptone-containing medium was compared with the growth of *Clostridium botulinum* in an APF medium disclosed in US Patent No. 8,012,716 (Allergan) (Table 2).

[83]

[84] Table 2 shows the components of the medium for culture of *Clostridium botulinum*, which contains plant-derived peptones, minerals, amino acids and vitamins.

[85]

[86] [Table 2]

Components of Medium	g/L	medium that is in current use	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	APF Medium of Allergan Company
Glucose	10	10	10	10	10	10	15
Sodium Chloride (NaCl)	0.42	0.42	0.42	0.42	0.42	0.42	-
Casein hydrolysate	20	20	20	-	-	-	-
Yeast extract	10	10	10	-	-	-	12
Thioglycollate medium	5	5	-	-	-	-	-
Hy-Pea™ 7404	20	-	-	20	40	20	-
UltraPep™ Cotton	10	-	-	10	20	10	-
HyPep™ 7504	10	-	-	10	20	10	-
HyPep™ 4601N	10	-	-	10	20	10	-
KH ₂ PO ₄	7	-	-	-	-	7	-
K ₂ HPO ₄	5.5	-	-	-	-	5.5	-
Na ₂ HPO ₄	5	-	-	-	-	5	-
MgSO ₄ 7H ₂ O	10	-	-	-	-	10	-
Vitamin Klt 100X		-	-	-	-	1X	-
Amino acid mixture 50X		-	-	-	-	1X	-
Soy peptone	32.5	-	-	-	-	-	32.5

[87]

[88] As a result, as shown in Table 2 and FIG. 2, when the bacterium was cultured in the medium that is in current use without thioglycollate, the growth rate of the bacterium

in the medium was slower than that in the thioglycollate-containing medium, indicating that thioglycollate influences the growth rate of the bacterium. When the peptone concentration in the medium was increased two times, the bacterium did not grow in the medium. When in the case in which mineral components, amino acids and vitamins were added to the peptone-containing medium, the growth rate of the bacterium was similar to that in the medium that is in current use, but a precipitate was formed after sterilization of the medium. In addition, it was seen that the growth rate of the bacterium in the Allergan's APF medium was similar to that in the medium that is in current use.

[89]

[90] Example 3: Production of Precipitate by Sterilization of Medium Containing Plant-derived Peptones, Minerals, Amino Acid and Vitamin

[91] In Example 2, it was observed that the growth rate of *Clostridium botulinum* in the medium containing plant-derived peptones, minerals, amino acids and vitamins, among the APF medium candidates 2 to 4 shown in Table 2, was similar that in the medium that is in current use. However, formation of a precipitate appeared after sterilization of the medium, and thus the cause thereof was examined (Table 3).

[92]

[93] Table 3 shows the components of a medium for culture of *Clostridium botulinum*, which was used in sterilization and contain plant-derived peptones, minerals, amino acids and vitamins.

[94]

[95] [Table 3]

Components of Medium	g/L	medium that is in current use	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)
Glucose	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5
Casein hydrolysate	20	20	-	-	-	-
Yeast extract	10	10	-	-	-	-
Thioglycollate medium	5	5	-	-	-	-
Hy-Pea™ 7404	20	-	20	20	20	20
UltraPep™ Cotton	10	-	10	10	10	10
HyPep™ 7504	10	-	10	10	10	10
HyPep™ 4601N	10	-	10	10	10	10
KH ₂ PO ₄	7	-	7	7	-	-
K ₂ HPO ₄	5.5	-	5.5	5.5	-	-
Na ₂ HPO ₄	5	-	5	5	-	-
MgSO ₄ 7H ₂ O	10	-	10	10	-	-
Vitamin Kit 100X		-	1X	-	1X	1X (Adding after Sterilization)
Amino acid mixture 50 X		-	1X	-	1X	1X (Adding after Sterilization)

[96]

[97] As a result, as shown in Table 3 and FIG. 3, only in the case in which minerals were added to the plant-derived peptone-containing medium, a precipitate was formed after sterilization of the medium, indicating that the main cause of formation of the precipitate was the minerals. This is believed to be because the mineral components interacted with one another under the conditions of high temperature and high pressure during sterilization of the medium.

[98]

[99] Example 4: Formation of Precipitate by Sterilization of Medium Containing Plant-derived Peptones and Minerals

[100] In order to identify the mineral components involved in the formation of precipitate caused by sterilization as confirmed in Example 3, various combinations of different components were added to media, followed by sterilization (Table 4).

[101]

[102] Table 4 shows the components of media for culture of *Clostridium botulinum*, which

contain plant-derived peptones and minerals, and the results of sterilization of the media.

[103]

[104] [Table 4]

Components of Medium	g/L	medium that is in current use	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	5 (APF Medium Candidate)	6 (APF Medium Candidate)	7 (APF Medium Candidate)	8 (APF Medium Candidate)	9 (APF Medium Candidate)	10 (APF Medium Candidate)	11 (APF Medium Candidate)	12 (APF Medium Candidate)
Glucose	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Casein hydrolysate	20	20	-	-	-	-	-	-	-	-	-	-	-	-
Yeast extract	10	10	-	-	-	-	-	-	-	-	-	-	-	-
Thioglycollate medium	5	5	-	-	-	-	-	-	-	-	-	-	-	-
Hy-Pea™ 7404	20	-	20	20	20	20	20	20	20	20	20	20	20	20
UltraPep™ Cotton	10	-	10	10	10	10	10	10	10	10	10	10	10	10
HyPep™ 7504	10	-	10	10	10	10	10	10	10	10	10	10	10	10
HyPep™ 4601N	10	-	10	10	10	10	10	10	10	10	10	10	10	10
KH ₂ PO ₄	7	-	-	7	-	7	7	7	-	7	7	-	-	10
K ₂ HPO ₄	5.5	-	-	5.5	5.5	-	5.5	5.5	-	-	5.5	5.5	5.5	-
Na ₂ HPO ₄	5	-	-	5	5	5	-	5	5	-	-	5	-	5
MgSO ₄ ·7H ₂ O	10	-	-	10	10	10	10	-	10	10	-	-	10	-
precipitation, aggregation			x	o	o	o	o	x	o	x	x	x	o	x

[105]

[106] As a result, as shown in Table 4 and FIG. 4, among the media containing plant-derived peptones and minerals, the medium containing MgSO₄·7H₂O and K₂HPO₄ and the medium containing MgSO₄·7H₂O and Na₂HPO₄ formed a precipitate after sterilization.

[107]

[108] Example 5: Culture of *Clostridium botulinum* under Conditions in which no Precipitate is formed in APF Medium

[109] An experiment was performed to determine whether culture of *Clostridium botulinum* is possible when vitamins and amino acids are additionally added to the APF medium of Example 4 containing plant-derived peptones and minerals. In addition, an experiment was performed to examine whether culture of the bacterium is possible in a medium which is free of plant-derived peptone and mineral and contains vitamins, amino acids and/or "BD Recharge™ without Glucose and L-Glutamine" (Cat No. 670002, BD Bioscience) (a yeast extract-based medium component free of glucose and L-glutamine) (Table 5).

[110]

[111] Table 5 shows the components of media obtained by additionally adding vitamins, amino acids and "BD Recharge™ without Glucose and L-Glutamine" to the medium for culture of *Clostridium botulinum*, which contains plant-derived peptones and minerals, and the growth rates of the bacterium in the media.

[112]

[113] [Table 5]

Components of Medium	g/L	medium that is in current use	1 (APF Medium Candida)	2 (APF Medium Candida)	3 (APF Medium Candida)	4 (APF Medium Candida)	5 (APF Medium Candida)	6 (APF Medium Candida)	7 (APF Medium Candida)	8 (APF Medium Candida)	9 (APF Medium Candida)	10 (APF Medium Candida)	11 (APF Medium Candida)	12 (APF Medium Candida)
Glucose	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Casein hydrolysate	20	20	-	-	-	-	-	-	-	-	-	-	-	-
Yeast extract	10	10	-	-	-	-	-	-	-	-	-	-	-	-
Thioglycollate medium	5	5	-	-	-	-	-	-	-	-	-	-	-	-
Sodium thioglycollate	1	-	-	-	-	-	-	-	-	-	1	-	-	-
Hy-Pea™ 7404	20	-	20	20	20	20	20	20	20	20	20	20	-	-
UltraPep™ Cotton	10	-	10	10	10	10	10	10	10	10	10	10	-	-
HyPep™ 7504	10	-	10	10	10	10	10	10	10	10	10	10	-	-
HyPep™ 4601N	10	-	10	10	10	10	10	10	10	10	10	10	-	-
KH ₂ PO ₄	7	-	-	7	7	7	-	7	-	-	-	-	-	-
K ₂ HPO ₄	5.5	-	-	5.5	-	5.5	5.5	-	-	-	-	-	-	-
Na ₂ HPO ₄	5	-	-	5	-	-	5	5	-	-	-	-	-	-
MgSO ₄ ·7H ₂ O	10	-	-	-	10	-	-	-	-	-	-	-	-	-
Vitamin Kit 100X		-	-	1X	1X	1X	1X	1X	1X	-	-	1X	-	1X
Amino acid mixture 50 X		-	-	1X	1X	1X	1X	1X	1X	-	-	1X	-	1X
w/o Glucose and L-glutamine	45.42	-	-	-	-	-	-	-	-	45.42	-	45.42	45.42	45.42
Growth			x	o	x	o	o	o	x	x	x	x	x	o
Details				Grown in 24hrs		Grown in 24hrs	Grown in 24hrs	Grown in 24hrs						Grown in 48hrs

[114]

[115] As a result, as shown in Table 5 and FIG. 5, only in the case in which the medium contained plant-derived peptones and a combination of two or more minerals of KH₂PO₄, K₂HPO₄ and Na₂HPO₄ and further contained vitamins and amino acids, *Clostridium botulinum* grew within 24 hours after inoculation of the bacterium. In addition, in the case in which the medium was free of plant-derived peptone and mineral and contained vitamins, amino acids and "BD Recharge™ without Glucose

and L-Glutamine", the bacterium grew within 48 hours after inoculation of the bacterium. In conclusion, the most suitable medium composition for culture of *Clostridium botulinum* comprises plant-derived peptones, KH_2PO_4 , K_2HPO_4 , Na_2HPO_4 , amino acids and vitamins.

[116]

[117] Example 6: Culture of *Clostridium botulinum* in Media Containing Different Plant-derived Peptones

[118] An experiment was performed to examine whether culture of *Clostridium botulinum* is possible when different combinations of plant-derived peptones are added to the APF medium of Example 5.

[119]

[120] Table 6 shows the components of media for culture of *Clostridium botulinum*, which contain different plant-derived peptones, and the results of examining whether the bacterium grew in the media.

[121]

[122] [Table 6]

Components of Medium	g/L	medium that is in current use	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	5 (APF Medium Candidate)	6 (APF Medium Candidate)	7 (APF Medium Candidate)	8 (APF Medium Candidate)	9 (APF Medium Candidate)	10 (APF Medium Candidate)	11 (APF Medium Candidate)	12 (APF Medium Candidate)	13 (APF Medium Candidate)
Glucose	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Casein hydrolysate	20	20	-	-	-	-	-	-	-	-	-	-	-	-	-
Yeast extract	10	10	-	-	-	-	-	-	-	-	-	-	-	-	-
Thioglycollate medium	5	5	-	-	-	-	-	-	-	-	-	-	-	-	-
Sodium thioglycollate	0.1	-	-	-	-	-	-	-	-	-	-	-	-	0.1	-
Hy-Pea™ 7404	10	-	10	10	-	-	-	-	-	-	10	10	10	-	-
UltraPep™ Cotton	10	-	10	-	10	-	-	-	10	10	-	-	10	-	-
HyPep™ 7504	10	-	10	-	-	10	-	10	-	10	-	10	-	-	-
HyPep™ 4601N	10	-	10	-	-	-	10	10	10	-	10	-	-	-	-
KH_2PO_4	7	-	7	7	7	7	7	7	7	7	7	7	7	-	7
K_2HPO_4	5.5	-	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	-	5.5
Na_2HPO_4	5	-	5	5	5	5	5	5	5	5	5	5	5	-	5
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vitamin Kit 100X	-	-	-	1X	1X	1X	1X	1X	1X	1X	1X	1X	1X	1X	1X
Amino acid mixture 50 X	-	-	-	1X	1X	1X	1X	1X	1X	1X	1X	1X	1X	1X	1X
w/o Glucose and L-glutamine	45.42	-	-	-	-	-	-	-	-	-	-	-	-	45.42	45.42
Growth			o	o	o	o	o	o	o	o	o	o	o	x	x

[123]

[124] As a result, as shown in Table 6 and FIG. 6, even when only or two of the four plant-derived peptones were added to the medium, culture of *Clostridium botulinum* was possible.

[125] Taking the results of Examples 5 and 6 into account, it could be seen that at least one plant-derived peptone should be contained in the medium and that the plant-derived

peptone cannot be substituted with "BD Recharge™ without Glucose and L-Glutamine" (Cat No. 670002, BD Bioscience) (a yeast extract-based medium component free of glucose and L-glutamine).

[126]

[127] Example 7: Experiment for Selection of Two of Three types of Minerals Contained in Medium

[128] In Examples 1 to 7, it was determined that the APF medium composition used for culture of *Clostridium botulinum* comprises glucose, sodium chloride (NaCl), four plant-derived peptones, three minerals, amino acids, and vitamins. Among these medium components, medium components having no significant effect on the growth of the bacterium were removed to reduce the number of the medium components. Thus, it was judged that amino acids and vitamins have no significant effect on the growth of *Clostridium botulinum*, and under this judgment, amino acids and vitamins were removed from the medium components. In addition, in order to select two from three types of minerals, the bacterium was cultured using the medium compositions shown in Table 7, and the OD (540 nm and 600 nm) values at 24 hours and 48 hours after inoculation of the bacterium were measured and compared.

[129]

[130] Table 7 shows the compositions of media resulting from the first-stage selection of minerals and the growth of *Clostridium botulinum* in the media.

[131]

[132] [Table 7]

Components of Medium	g/L	medium that is in current use	1 (APF Medium m Candidiate)	2 (APF Medium m Candidiate)	3 (APF Medium m Candidiate)	4 (APF Medium m Candidiate)	5 (APF Medium m Candidiate)	6 (APF Medium m Candidiate)	7 (APF Medium m Candidiate)	8 (APF Medium m Candidiate)	9 (APF Medium m Candidiate)	10 (APF Medium m Candidiate)	11 (APF Medium m Candidiate)
Glucose	10	10	10	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Caseln hydrolysate	20	20	-	-	-	-	-	-	-	-	-	-	-
Yeast extract	10	10	-	-	-	-	-	-	-	-	-	-	-
Thioglycollate medium	5	5	-	-	-	-	-	-	-	-	-	-	-
Hy-Pea™ 7404	10	-	10	10	10	10	10	10	10	10	10	10	10
UltraPep™ Cotton	10	-	10	10	10	10	10	10	10	10	10	10	10
HyPep™ 7504	10	-	10	10	10	10	10	10	10	10	10	10	10
HyPep™ 4601N	10	-	10	10	10	10	10	10	10	10	10	10	10
KH ₂ PO ₄	7	-	-	7	-	7	-	7	-	7	3.5	3.5	3.5
K ₂ HPO ₄	5.5	-	-	-	5.5	5.5	-	-	5.5	5.5	2.75	2.75	2.75
Na ₂ HPO ₄	5	-	-	-	-	5	5	5	5	5	2.5	2.5	2.5
Culture 24hr OD	540nm	0.942	-0.017	-0.024	4.396	3.226	4.218	3.214	4.964	3.991	3.951	3.938	3.594
	600nm	0.780	-0.016	-0.020	3.832	2.691	3.593	2.680	4.304	3.351	3.341	3.335	3.036
Culture 48hr OD	540nm	2.459	-0.014	-0.019	4.716	5.220	3.502	5.460	2.056	2.603	5.726	5.682	5.434
	600nm	2.057	-0.015	-0.018	3.852	4.288	2.989	4.480	1.587	2.020	4.688	4.647	4.459

[133]

[134] As a result, as shown in Table 7, at 24 hours after inoculation of the bacterium, the medium that is in current use showed an OD(540nm) value of 0.942, and the APF medium containing K₂HPO₄ and Na₂HPO₄ showed the highest OD(540nm) value of 4.964 among the APF media. In addition, at 48 hours after inoculation of the bacterium, the APF medium containing KH₂PO₄ and Na₂HPO₄ showed the highest OD value and active bacterial growth.

[135] Meanwhile, as shown in FIG. 7a to Fig. 7d, contour plots of K₂HPO₄ and Na₂HPO₄ showing high main effects were drawn. As a result, as the concentrations of K₂HPO₄ and Na₂HPO₄ increased, the OD value increased. And *Clostridium botulinum* showed the highest growth when minerals were added to the medium at the concentrations of KH₂PO₄ = 0 g/L, K₂HPO₄ = 5.5 g/L, and Na₂HPO₄ = 5 g/L.

[136] Meanwhile, in order to confirm the results of bacterial culture according to more precise addition of minerals, a second-stage experiment was performed using response surface methodology. Because the medium composition cannot have a negative value, the experiment was planned using a CCF (central composite faced) design and performed by culturing the bacterium in the medium compositions shown in Table 8. Then, the experimental results were combined with the results of the previously performed FFD and subjected to statistical analysis.

[137]

[138] Table 8 shows the compositions of media obtained by the second-stage selection of minerals and the growth of *Clostridium botulinum* in the media.

[139]

[140] [Table 8]

Components of Medium	g/L	1 (APF Medium Candida te)	2 (APF Mediu m Candid ate)	3 (APF Mediu m Candid ate)	4 (APF Mediu m Candid ate)	5 (APF Mediu m Candid ate)	6 (APF Mediu m Candid ate)	7 (APF Mediu m Candid ate)	8 (APF Mediu m Candid ate)	9 (APF Mediu m Candid ate)	medi um that is in curre nt use
Glucose	10	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	-
Casein hydrolysate	20	-	-	-	-	-	-	-	-	-	20
Yeast extract	10	-	-	-	-	-	-	-	-	-	10
Thioglycollate medium	5	-	-	-	-	-	-	-	-	-	5
Hy-Pea™ 7404	10	10	10	10	10	10	10	10	10	10	-
UltraPep™ Cotton	10	10	10	10	10	10	10	10	10	10	-
HyPep™ 7504	10	10	10	10	10	10	10	10	10	10	-
HyPep™ 4601N	10	10	10	10	10	10	10	10	10	10	-
KH ₂ PO ₄	7	-	7	3.5	3.5	3.5	3.5	3.5	3.5	3.5	-
K ₂ HPO ₄	5.5	2.75	2.75	-	5.5	2.75	2.75	2.75	2.75	2.75	-
Na ₂ HPO ₄	5	2.5	2.5	2.5	2.5	-	5	2.5	2.5	2.5	-
OD 24hr	540nm	4.408	3.587	2.233	4.639	1.778	4.332	3.904	3.907	4.046	1.556
	600nm	3.836	3.086	1.896	4.068	1.503	3.777	3.366	3.368	3.505	1.307
OD 48hr	540nm	5.021	5.760	4.359	3.594	4.529	4.054	6.492	5.621	5.473	3.622
	600nm	4.284	4.925	3.695	3.049	3.832	3.457	5.603	4.830	4.677	3.062

[141]

[142] Contour plots were drawn and used for comparison. As shown in FIGs. 8a to 8d, the OD value increased as the concentration of KH₂PO₄ decreased. When the optimal conditions were compared, the results were different from the results of FFD due to the curvature effect, and the value of K₂HPO₄ was the same, but the value of Na₂HPO₄ changed from 5 g/L to 3.1313 g/L. Thus, it was confirmed that the optimal mineral conditions of the medium by statistical analysis are 5.5 g/L K₂HPO₄ and 3 g/L Na₂HPO₄

4.

[143]

[144] Example 8: Experiment for Selection of Plant-derived Peptones Contained in Medium

[145] As shown in Tables 9 and 10, plant-derived peptones were combined according to a mixture design, and the growth of *Clostridium botulinum* in a medium containing the combined plant-derived peptones was examined.

[146]

[147] Table 9 shows the compositions of media obtained by the first-stage selection of plant-derived peptones and the growth of *Clostridium botulinum* using the media.

[148]

[149] [Table 9]

Components of Medium	g/L	1 (APF Medium Candida ate)	2 (APF Medium Candida ate)	3 (APF Medium Candida ate)	4 (APF Medium Candida ate)	5 (APF Medium Candida ate)	6 (APF Medium Candida ate)	7 (APF Medium Candida ate)	8 (APF Medium Candida ate)	9 (APF Medium Candida ate)	10 (APF Medium Candida ate)	11 (APF Medium Candida ate)	medi um that is in curre nt use
Glucose	10	10	10	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	-
Casein hydrolysate	20	-	-	-	-	-	-	-	-	-	-	-	20
Yeast extract	10	-	-	-	-	-	-	-	-	-	-	-	10
Thioglycollate medium	5	-	-	-	-	-	-	-	-	-	-	-	5
Hy-Pea™ 7404	10	5	10	5	5	-	-	6.667	6.667	-	-	10	-
UltraPep™ Cotton	10	5	-	5	5	10	-	6.667	6.667	20	-	10	-
HyPep™ 7504	10	5	10	5	5	-	10	-	6.667	-	20	10	-
HyPep™ 4601N	10	5	-	5	5	10	10	6.667	-	-	-	10	-
K ₂ HPO ₄	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	-
Na ₂ HPO ₄	3	3	3	3	3	3	3	3	3	3	3	3	-
OD 24hr	540nm	3.541	2.440	3.345	3.305	3.317	2.852	3.695	2.772	2.353	1.688	4.842	2.239
	600nm	3.058	2.066	2.868	2.831	2.853	2.445	3.183	2.376	2.014	1.419	4.245	1.893
OD 48hr	540nm	0.811	0.935	0.731	0.799	1.400	0.777	1.660	1.090	1.810	1.402	2.093	3.341
	600nm	0.714	0.795	0.647	0.694	1.199	0.680	1.403	0.929	1.548	1.210	1.764	2.812

[150]

[151] Table 10 shows the compositions of media obtained by the second-stage selection of plant-derived peptones and the growth of *Clostridium botulinum* using the media.

[152]

[153] [Table 10]

Components of Medium	g/L	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	5 (APF Medium Candidate)	6 (APF Medium Candidate)	7 (APF Medium Candidate)	8 (APF Medium Candidate)	9 (APF Medium Candidate)	10 (APF Medium Candidate)	11 (APF Medium Candidate)	12 (APF Medium Candidate)	13 (APF Medium Candidate)	medium that is in current use
Glucose	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	-
Casein hydrolysate	20	-	-	-	-	-	-	-	-	-	-	-	-	-	20
Yeast extract	10	-	-	-	-	-	-	-	-	-	-	-	-	-	10
Thioglycollate medium	5	-	-	-	-	-	-	-	-	-	-	-	-	-	5
Hy-Pea™ 7404	10	5	5	-	-	10	10	5	20	-	6.667	10	10	10	-
UltraPep™ Cotton	10	5	5	10	6.667	10	-	5	-	-	-	10	10	10	-
HyPep™ 7504	10	5	5	10	6.667	-	-	5	-	-	6.667	10	10	10	-
HyPep™ 4601N	10	5	5	-	6.667	-	10	5	-	20	6.667	10	10	10	-
K ₂ HPO ₄	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	-
Na ₂ HPO ₄	3	3	3	3	3	3	3	3	3	3	3	3	3	3	-
OD 24hr	540nm	3.425	3.640	2.349	2.581	3.272	1.289	3.514	0.776	1.257	3.457	5.376	5.235	4.809	2.208
	600nm	2.969	3.159	2.029	2.244	1.096	1.096	3.032	0.649	1.098	2.950	4.689	4.534	4.246	1.863
OD 48hr	540nm	0.769	0.836	1.633	0.961	1.501	1.148	0.803	0.880	1.278	0.962	1.986	1.994	2.010	3.185
	600nm	0.675	0.732	1.420	0.854	1.270	0.982	0.698	0.744	1.124	0.818	1.708	1.710	1.717	2.708

[154]

[155] As a result, as shown in FIGs. 9a to 9c, contour plots were drawn and used for analysis. It was determined that HyPep™ 7504 corresponding to the component C has the lowest effect on the growth of *Clostridium botulinum*. Based on this determination, HyPep™ 7504 was excluded from medium components. In conclusion, it was determined that the composition of the finally selected plant-derived peptones that are contained in the medium comprises 5 g/L Hy-Pea™ 7404, 10 g/L UltraPep™ Cotton and 5 g/L HyPep™ 4601N.

[156]

[157] Example 9: Culture of *Clostridium botulinum* in Medium Containing or Not Containing NaCl

[158] The medium compositions used in Examples 1 to 8 contained a small amount (0.5 g/L) of NaCl. In order to examine the growth of *Clostridium botulinum* according to the concentration change of NaCl, the content of NaCl in the medium was adjusted to a range from 0 to 1 g/L, followed by culture of the bacterium in the medium.

[159]

[160] Table 11 shows the components of NaCl-containing media for culture of *Clostridium botulinum* and the growth of *Clostridium botulinum* in the media.

[161]

[162] [Table 11]

Components of Medium	g/L	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	5 (APF Medium Candidate)	6 (APF Medium Candidate)	7 (APF Medium Candidate)	8 (APF Medium Candidate)	9 (APF Medium Candidate)
Glucose	10	10	10	10	10	10	10	10	10	10
Sodium Chloride (NaCl)	0.5	-	-	-	0.5	0.5	0.5	1	1	1
Hy-Pea™ 7404	5	5	5	5	5	5	5	5	5	5
UltraPep™ Cotton	10	10	10	10	10	10	10	10	10	10
HyPep™ 4601N	5	5	5	5	5	5	5	5	5	5
K ₂ HPO ₄	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5	5.5
Na ₂ HPO ₄	3	3	3	3	3	3	3	3	3	3
OD 24hr	540nm	2.166	2.154	2.151	2.148	2.115	2.120	2.145	2.147	2.140
	600nm	1.940	1.923	1.922	1.922	1.892	1.896	1.919	1.922	1.917

[163]

[164] As a result, as shown in FIG. 11, there was no difference in the growth of the bacterium whether the medium contained NaCl or not. Thus, NaCl was excluded from the final APF medium components.

[165]

[166] Example 10: Measurement of Growth Pattern of *Clostridium botulinum* in Finally Selected APF Medium and Toxin Concentration

[167] *Clostridium botulinum* was inoculated into the finally selected *Clostridium botulinum* culture medium (10 g/L glucose, 5 g/L Hy-Pea™ 7404, 10 g/L UltraPep™ Cotton, 5 g/L HyPep™ 4601N, 5.5 g/L K₂HPO₄, and 3 g/L Na₂HPO₄) determined based on the results of Examples 1 to 9, and then the growth pattern of the bacterium and the toxin concentration were measured.

[168]

[169] Table 12 shows the time-dependent OD value and the toxin concentration of *Clostridium botulinum* grown in the finally selected APF medium.

[170]

[171] [Table 12]

Time of Culture (hr)	OD		Toxin Conc. in Supernatant ($\mu\text{g/ml}$)	Total Toxin Conc. after rupturing strain ($\mu\text{g/ml}$)
	540nm	600nm		
0	0	0	0	0
6	0.0953	0.0393	0.00	0.00
9	0.0648	0.0525	0.00	0.00
12	0.5003	0.4411	0.00	0.00
14	1.1328	0.9958	2.18	2.04
16	1.6252	1.4484	4.64	10.22
18	2.3435	2.0215	6.77	18.15
20	2.777	2.4015	8.47	29.26
22	3.3485	2.896	9.46	31.86
24	3.5465	3.0695	-	31.73
28	3.452	2.982	-	37.31
36	2.5955	2.242	21.20	38.00
48	0.792	0.7224	31.41	38.39

[172]

[173] As a result, as shown in Table 12 and FIG. 10, the OD value started to increase after 12 hours of culture of *Clostridium botulinum*, and at 24 hours of culture, the culture medium showed an OD_{540nm} of 3.5465 and an OD_{600nm} of 3.0695. Then, the OD value decreased gradually, and at 48 hours of culture, the culture medium showed an OD_{540nm} of 0.792 and an OD_{600nm} of 0.7224. The toxin concentration in the supernatant of *Clostridium botulinum* started to increase after 24 hours of culture and showed a final value of 31.41 $\mu\text{g/ml}$. When the toxin concentration was measured after rupturing the bacterium, the toxin started to be produced after 5 hours of culture, and the toxin concentration continued to increase, was maintained at a uniform level after 28 hours of culture, and showed a final value of 38.39 $\mu\text{g/ml}$.

[174] In conclusion, the finally selected APF (animal protein-free medium) composition determined based on the results of Examples 1 to 10 is summarized in Table 13.

[175]

[176] [Table 13]

Components of Medium		g/L
Carbon Source	Glucose	10
Nitrogen Source (Vegetable Peptone)	Hy-Pea™ 7404	5
	UltraPep™ Cotton	10
	HyPep™ 4601N	5
Mineral	K₂HPO₄	5.5
	Na₂HPO₄	3

[177]

Industrial Applicability

[178] As described above, when the medium according to the present invention, which contains plant-derived peptones and minerals, is used for culture of *Clostridium botulinum*, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.


[179]

[180] Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.


Claims

- [Claim 1] A medium composition for culture of *Clostridium botulinum*, the medium composition comprising:
at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate.
- [Claim 2] The medium composition of claim 1, wherein the plant-derived peptone is comprised with content of 0.1-10 w/v%.
- [Claim 3] The medium composition of claim 1, wherein the medium composition comprising the garden pea hydrolysate, the cotton seed hydrolysate and the wheat gluten hydrolysate in the medium composition with a ratio of 1:0.24-43.62:0.01-50.57 by weight, provided if the medium composition comprising the garden pea hydrolysate, the cotton seed hydrolysate and the wheat gluten hydrolysate.
- [Claim 4] The medium composition of claim 1, wherein the plant-derived peptone is subjected to an enzyme treatment.
- [Claim 5] The medium composition of claim 1, further comprising a carbon source, and at least one mineral selected from the group consisting of K_2HPO_4 (dipotassium phosphate), Na_2HPO_4 (disodium phosphate) and KH_2PO_4 (monopotassium phosphate).
- [Claim 6] The medium composition of claim 5, wherein the mineral is comprised in the medium composition with content of 0.05-3.5 w/v%.
- [Claim 7] A method for producing botulinum toxin, comprising the steps of:
(a) culturing *Clostridium botulinum* using the medium composition of any one of claims 1 to 6 to produce botulinum toxin; and
(b) recovering the produced botulinum toxin.
- [Claim 8] The method of claim 7, wherein the culture is performed under anaerobic conditions.
- [Claim 9] The method of claim 7, wherein the botulinum toxin is selected from the group consisting of botulinum toxin serotypes A, B, C, D, E, F and G.


[Fig. 1]





[Fig. 2]




[Fig. 3]



[Fig. 4]

Types of Medium	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	5 (APF Medium Candidate)	6 (APF Medium Candidate)
						
Precipitation	x	o	o	o	o	x
Types of Medium	7 (APF Medium Candidate)	8 (APF Medium Candidate)	9 (APF Medium Candidate)	10 (APF Medium Candidate)	11 (APF Medium Candidate)	12 (APF Medium Candidate)
						
Precipitation	o	x	x	x	o	x


[Fig. 5]

Types of Medium	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	5 (APF Medium Candidate)	6 (APF Medium Candidate)
						
Growth	x	o	x	o	o	o
Types of Medium	7 (APF Medium Candidate)	8 (APF Medium Candidate)	9 (APF Medium Candidate)	10 (APF Medium Candidate)	11 (APF Medium Candidate)	12 (APF Medium Candidate)
						
Growth	x	x	x	x	x	o


[Fig. 6]

Types of Medium	1 (APF Medium Candidate)	2 (APF Medium Candidate)	3 (APF Medium Candidate)	4 (APF Medium Candidate)	5 (APF Medium Candidate)	6 (APF Medium Candidate)	7 (APF Medium Candidate)	8 (APF Medium Candidate)	9 (APF Medium Candidate)	10 (APF Medium Candidate)	11 (APF Medium Candidate)	12 (APF Medium Candidate)	13 (APF Medium Candidate)
													
Growth	0	0	0	0	0	0	0	0	0	0	0	X	X


[Fig. 7a]




[Fig. 7b]




[Fig. 7c]




[Fig. 7d]




[Fig. 8a]




[Fig. 8b]




[Fig. 8c]




[Fig. 8d]




[Fig. 9a]




[Fig. 9b]



[Fig. 9c]



[Fig. 10]



A. CLASSIFICATION OF SUBJECT MATTER**C12N 5/00(2006.01)i, C07K 14/33(2006.01)i, C12R 1/145(2006.01)n**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12N 5/00; C07K 14/33; C12P 21/00; C12P 21/04; A61K 39/08; C12N 1/20; C12R 1/145

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & keywords: Clostridium botulinum, plant-derived peptone, toxin, medium, garden pea, cotton seed, wheat gluten, hydrolysate

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2005-0069562 A1 (DONOVAN, S.) 31 March 2005 See paragraphs [0047], [0067]-[0068], [0070], [0074], [0079] and [0080]; claims 1-6.	1-9
Y	FANG, AIQI et al., 'Production of Clostridium difficile toxin in a medium totally free of both animal and dairy proteins or digests', PNAS, 11 August 2009, Vol. 106, No. 32, pp. 13225-13229 See abstract; Table 2; 'Materials and Methods' section	1-9
A	KR 10-2009-0120222 A (MEDYTOX INC.) 24 November 2009 See abstract; paragraphs [47]-[50]; claims 1-4.	1-9
A	WO 01-05997 A2 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 25 January 2001 See claims 34-40.	1-9
A	GESSLER, F., 'A new scaleable method for the purification of botulinum neurotoxin type E.', J. Biotechnol., 23 September 2005, Vol. 119, No. 2, pp. 204-211 See abstract; page 205, right column - page 206, left column.	1-9



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered
to be of particular relevance"E" earlier application or patent but published on or after the international
filing date"L" document which may throw doubts on priority claim(s) or which is
cited to establish the publication date of another citation or other
special reason (as specified)"O" document referring to an oral disclosure, use, exhibition or other
means"P" document published prior to the international filing date but later
than the priority date claimed"T" later document published after the international filing date or priority
date and not in conflict with the application but cited to understand
the principle or theory underlying the invention"X" document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone"Y" document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 September 2016 (21.09.2016)

Date of mailing of the international search report

22 September 2016 (22.09.2016)

Name and mailing address of the ISA/KR

International Application Division

Korean Intellectual Property Office


189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer

HEO, Joo Hyung

Telephone No. +82-42-481-8150



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2016/004430

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2005-0069562 A1	31/03/2005	AU 2004-280450 A1	21/04/2005
		AU 2004-280450 B2	05/02/2009
		AU 2005-293288 A1	20/04/2006
		AU 2005-293288 B2	02/06/2011
		AU 2005-327457 A1	05/10/2006
		AU 2005-327457 B2	23/08/2012
		AU 2005-327458 A1	05/10/2006
		AU 2005-327458 B2	15/12/2011
		AU 2006-295305 A1	05/04/2007
		AU 2006-295305 B2	31/01/2013
		BR PI0414722 A	21/11/2006
		CA 2540072 A1	21/04/2005
		CA 2556537 A1	03/09/2006
		CA 2556796 A1	03/09/2006
		CA 2850858 A1	05/04/2007
		CN 101119688 A	06/02/2008
		CN 1856569 A	01/11/2006
		CN 1856569 B	01/12/2010
		CN 1930186 A	14/03/2007
		CN 1946738 A	11/04/2007
		DK 1664292 T3	30/08/2010
		EP 1396243 A1	10/03/2004
		EP 1396243 B1	15/08/2007
		EP 1664292 A2	07/06/2006
		EP 1664292 B1	26/05/2010
		EP 1827325 A1	05/09/2007
		EP 1827325 B1	04/05/2011
		EP 1853622 A1	14/11/2007
		EP 1853622 B1	16/07/2014
		EP 1853623 A1	14/11/2007
		EP 1853623 B1	08/05/2013
		EP 1924292 A2	28/05/2008
		EP 2177607 A1	21/04/2010
		EP 2335658 A1	22/06/2011
		ES 2344843 T3	08/09/2010
		JP 2007-506427 A	22/03/2007
		JP 2008-515582 A	15/05/2008
		JP 2008-531046 A	14/08/2008
		JP 2008-531047 A	14/08/2008
		JP 2009-508857 A	05/03/2009
		JP 2012-041356 A	01/03/2012
		JP 2012-070759 A	12/04/2012
		JP 2012-125251 A	05/07/2012
		JP 2013-014600 A	24/01/2013
		JP 2015-051019 A	19/03/2015
		JP 4712807 B2	29/06/2011
		JP 4913074 B2	11/04/2012
		JP 5006803 B2	22/08/2012
		JP 5122460 B2	16/01/2013

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2016/004430

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP 5518024 B2	11/06/2014
		JP 5567082 B2	06/08/2014
		KR 10-1100567 B1	29/12/2011
		KR 10-2006-0102330 A	27/09/2006
		KR 10-2007-0104334 A	25/10/2007
		KR 10-2007-0115580 A	06/12/2007
		KR 10-2007-0116710 A	11/12/2007
		MX PA06003029 A	23/06/2006
		NZ 545503 A	30/04/2009
		US 2005-0143765 A1	30/06/2005
		US 2005-0143766 A1	30/06/2005
		US 2005-0238668 A1	27/10/2005
		US 2005-0238669 A1	27/10/2005
		US 2005-0251182 A1	10/11/2005
		US 2006-0228777 A1	12/10/2006
		US 2006-0228780 A1	12/10/2006
		US 2006-0240514 A1	26/10/2006
		US 2007-0066541 A1	22/03/2007
		US 2007-0111288 A1	17/05/2007
		US 2008-0027469 A1	31/01/2008
		US 2009-0022763 A1	22/01/2009
		US 2009-0123497 A1	14/05/2009
		US 2009-0124790 A1	14/05/2009
		US 2009-0274729 A1	05/11/2009
		US 2010-0222587 A1	02/09/2010
		US 2011-0152608 A1	23/06/2011
		US 2014-0039250 A1	06/02/2014
		US 7148041 B2	12/12/2006
		US 7160699 B2	09/01/2007
		US 7189541 B2	13/03/2007
		US 7238191 B2	03/07/2007
		US 7354740 B2	08/04/2008
		US 7445914 B2	04/11/2008
		US 7452697 B2	18/11/2008
		US 7560251 B2	14/07/2009
		US 7714024 B2	11/05/2010
		US 7901419 B2	08/03/2011
		US 7972346 B2	05/07/2011
		US 8008044 B2	30/08/2011
		US 8012162 B2	06/09/2011
		US 8012716 B2	06/09/2011
		US 8637571 B2	28/01/2014
		WO 2005-035749 A2	21/04/2005
		WO 2005-035749 A3	02/06/2005
		WO 2006-040647 A1	20/04/2006
		WO 2006-096163 A1	14/09/2006
		WO 2006-096164 A1	14/09/2006
		WO 2007-037849 A2	05/04/2007
		WO 2007-037849 A3	24/01/2008

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2016/004430

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
KR 10-2009-0120222 A	24/11/2009	CN 102089438 A	08/06/2011
		EP 2276851 A1	26/01/2011
		EP 2733216 A1	21/05/2014
		JP 2011-520463 A	21/07/2011
		KR 10-1434558 B1	27/08/2014
		US 2011-0091937 A1	21/04/2011
		US 8993268 B2	31/03/2015
		WO 2009-142352 A1	26/11/2009
WO 01-05997 A2	25/01/2001	AU 2000-62138 A1	05/02/2001
		US 6558926 B1	06/05/2003
		WO 01-05997 A3	26/07/2001